查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1870423

血液血浆衍生产品市场：按来源、最终用户、分销管道、产品类型和应用划分 - 全球预测（2025-2032 年）

Blood Plasma Derivatives Market by Source, End User, Distribution Channel, Product Type, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，血浆衍生产品市场规模将达到 11.3421 亿美元，复合年增长率为 10.13%。

主要市场统计数据
基准年 2024 5.2383亿美元
预计年份：2025年 5.7603亿美元
预测年份：2032年 1,134,210,000 美元
复合年增长率 (%) 10.13%

这份报告清楚地概述了科学进步、供应链韧性以及不断演变的医疗服务模式，这些因素正在重塑患者获得血浆衍生和重组疗法的途径。

血浆衍生和重组生技药品治疗领域已进入一个以加速科学创新、监管重点转变和供应链运作复杂性日益增加为特征的阶段。重组技术的进步和生产控制的改进正在扩大可用的治疗方案范围，同时，诊断准确性和患者分层方面的进步正在完善血友病、原发性免疫力缺乏和某些神经系统疾病的临床治疗途径。

冷静地观点分子创新、日益严格的监管和数数位化如何重新定义血浆衍生和重组疗法的竞争格局

当前时代正经历着变革性的变化，这些变化正在重新定义血浆衍生疗法和重组疗法的研发、生产和交付方式。分子工程和细胞株优化技术的进步提高了重组凝血因子的特异性和稳定性，与血浆衍生免疫球蛋白和白蛋白的分离纯化技术的改进相辅相成。与这些科学进步同步的是整个生产和分销网络的日益数位化，从而在产品生命週期内实现了更强的可追溯性和品质保证。

分析评估美国关税政策的变化将如何导致各行业的供应链重组、采购转移和策略製造决策。

美国关税和贸易政策的发展正对全球血浆衍生和重组产品生态系统产生连锁反应。关税调整正在影响分离和重组生产所需的原材料、专用耗材和设备的成本结构。这些变化波及到契约製造关係和筹资策略，迫使製造商重新评估其采购基础和合约条款，以维持获利能力和可靠性。

一个基于细分市场的综合洞察框架，将原材料、终端用户、分销管道、产品类型和临床应用联繫起来，以发现重点策略领域。

细分市场分析突显了不同产品类别和给药模式的商业和临床驱动因素，从而深入观点了创新和投资的重点领域。按来源分類的市场细分区分了血浆衍生产品和重组产品两大类，并在重组产品中进一步检验了因子IX和因子VIII在临床和生产方面的差异。这些差异会影响研发週期、监管管道和临床医生的应用模式。最终使用者评估区分了血友病治疗中心、居家医疗机构和医院，这三者对低温运输管理、病患教育和依从性计划以及分销和支援服务都有各自独特的需求。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 新兴的重组白蛋白疗法减少了对捐血血浆蛋白的依赖。
  • 由于自体免疫疾病发生率不断上升，对免疫球蛋白的需求也随之增加。
  • 采用先进的病毒灭活技术提高血浆製品的安全性
  • 监管协调努力旨在加速血浆衍生疗法的全球核准
  • 血浆分馏公司与生技创新者之间的策略联盟
  • 在感染疾病控制和疫情应对中越来越多地使用高免疫球蛋白
  • 改用皮下注射免疫球蛋白可提高患者的遵从性和舒适度。
  • 推出数位化血浆捐献者管理平台，以优化血液采集和追踪
  • 投资建构一次性反应器系统，以实现分散式血浆分馏能力
  • 开发单株抗体佐剂，以与血浆分馏疗法结合，用于标靶治疗

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 血浆衍生产品市场：依原料划分

  • 血浆衍生
  • 重组
    • 因子IX
    • 因子 VIII

9. 按最终用户分類的血浆衍生产品市场

  • 血友病治疗中心
  • 居家医疗
  • 医院

10. 按分销管道分類的血浆衍生产品市场

  • 医院药房
  • 网路药房
  • 零售药房
  • 专科诊所

第十一章 按产品类型分類的血浆衍生产品市场

  • 白蛋白
  • 凝血因子
    • 因子IX
    • 因子 VIII
    • 纤维蛋白胶
  • 免疫球蛋白
    • 高免疫力製剂
    • 静脉注射
    • 皮下注射

第十二章 血浆衍生产品市场：依应用领域划分

  • 血友病治疗
  • 神经系统疾病
  • 原发性免疫力缺乏缺陷症

13. 按地区分類的血浆衍生产品市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 按组别分類的血浆衍生产品市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国血浆衍生产品市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • CSL Limited
    • Grifols, SA
    • Takeda Pharmaceutical Company Limited
    • Octapharma AG
    • Kedrion SpA
    • BIoTest AG
    • LFB SA
    • Bio Products Laboratory Limited
    • Shanghai RAAS Blood Products Co., Ltd.
    • China Biologic Products Holdings, Inc.
Product Code: MRR-1A1A064C008F

The Blood Plasma Derivatives Market is projected to grow by USD 1,134.21 million at a CAGR of 10.13% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 523.83 million
Estimated Year [2025] USD 576.03 million
Forecast Year [2032] USD 1,134.21 million
CAGR (%) 10.13%

An incisive overview framing scientific progress, supply chain resilience, and evolving care delivery models that are reshaping patient access to plasma-derived and recombinant therapeutics

The therapeutic landscape for blood plasma derivatives and recombinant biologics has entered a phase characterized by intensified scientific innovation, shifting regulatory priorities, and heightened operational complexity across supply chains. Advances in recombinant technologies and improved manufacturing controls have expanded the portfolio of available therapeutic options, while concurrent growth in diagnostic precision and patient stratification has refined clinical pathways for conditions such as hemophilia, primary immunodeficiency, and selected neurological disorders.

Alongside scientific progress, stakeholders face evolving expectations for product safety, traceability, and access. Manufacturers and providers must balance the imperative for rigorous donor screening and pathogen-reduction processes with the need to maintain continuity of supply. Health systems and treatment centers are increasingly integrating home-based care models and specialist clinic frameworks, prompting re-evaluation of distribution pathways and patient support mechanisms. Taken together, these dynamics set the stage for strategic decision-making by biopharmaceutical companies, clinicians, and payers who must adapt to an environment where therapeutic choice, supply resilience, and regulatory compliance converge.

A clear-eyed examination of how molecular innovations, regulatory tightening, and distribution digitalization are redefining competitive dynamics across plasma and recombinant therapeutics

The current period is marked by transformative shifts that are redefining how plasma-derived and recombinant therapies are developed, manufactured, and delivered. Breakthroughs in molecular engineering and cell-line optimization have increased the specificity and stability of recombinant coagulation factors, complementing improvements in fractionation and purification techniques for plasma-derived immunoglobulins and albumin. These scientific advances are paralleled by digitalization across manufacturing and distribution networks, enabling better traceability and quality assurance throughout the product lifecycle.

Regulatory authorities are placing greater emphasis on robust risk-mitigation strategies, including enhanced pathogen-detection protocols and lifecycle surveillance for novel biologics. At the same time, payers and health systems are prioritizing treatment modalities that demonstrate both clinical efficacy and operational efficiencies, driving adoption in home care settings and specialist clinics where appropriate. Market entrants and incumbents alike are forming strategic alliances to de-risk supply chains, scale capacity, and accelerate access to recombinant alternatives, thereby shifting competitive dynamics and incentivizing investments in vertical integration and regional manufacturing hubs. As a result, stakeholders must now navigate a landscape where scientific innovation, regulatory rigor, and commercial agility intersect to determine long-term positioning.

An analytical assessment of how changing United States tariff policies create supply chain realignments, procurement shifts, and strategic manufacturing decisions across the industry

Policy movements in the United States concerning tariffs and trade measures have had a cascading set of effects on the global ecosystem for plasma-derived and recombinant products. Tariff adjustments influence cost structures for raw materials, specialized consumables, and equipment needed for fractionation and recombinant production. These changes reverberate across contract manufacturing relationships and procurement strategies, prompting manufacturers to reassess sourcing footprints and contractual terms to preserve margin and reliability.

Beyond direct cost implications, tariff shifts can alter the geographic logic of supply chains, encouraging investments in regional production capabilities or in alternative supplier relationships to mitigate trade exposure. Health systems and distributors respond by diversifying their vendor base and by strengthening inventory management policies to accommodate potential disruptions. Clinicians and treatment centers may experience indirect effects through changes in product availability or delivery timelines, requiring increased coordination among manufacturers, distributors, and payers.

Finally, tariffs can influence strategic decision-making around product portfolios. Firms evaluating capital investments or portfolio expansions weigh trade-related risks alongside regulatory and clinical factors, with some opting to accelerate local capacity expansions or pursue licensing arrangements that reduce cross-border trade dependencies. Consequently, tariff measures serve as a significant exogenous variable that shapes operational choices, partnership strategies, and resilience planning across the sector.

A comprehensive segmentation-driven insight framework connecting source, end-user, distribution, product types, and clinical applications to reveal targeted strategic priorities

Segmentation analysis illuminates distinct commercial and clinical drivers across product classes and delivery models, offering a nuanced lens on where innovation and investment are concentrated. Based on Source, the market divides into plasma-derived and recombinant categories, with recombinant approaches further examined through the distinct clinical and manufacturing attributes of Factor IX and Factor VIII; these differences influence development timelines, regulatory pathways, and clinician adoption patterns. Based on End User, the evaluation distinguishes Hemophilia Treatment Centers, Home Care settings, and Hospitals, each presenting unique requirements for cold chain management, patient education, and adherence programs that shape distribution and support services.

Based on Distribution Channel, distribution pathways encompass Hospital Pharmacy, Online Pharmacies, Retail Pharmacy, and Specialist Clinics, creating diverse access points that affect point-of-care readiness and patient experience. Based on Product Type, product segmentation recognizes Albumin, Coagulation Factor, and Immunoglobulin, and further dissects the Coagulation Factor category into Factor IX, Factor VIII, and Fibrin Sealant while the Immunoglobulin group is evaluated across Hyperimmune, Intravenous, and Subcutaneous formulations; these product-level distinctions determine clinical use cases, preparation complexity, and storage considerations. Based on Application, therapeutic uses span Hemophilia Treatment, Neurological Disorders, and Primary Immunodeficiency, each driving specific clinical trial designs, outcome measures, and post-market surveillance needs. Synthesizing these segment-level insights enables stakeholders to align R&D focus, commercial strategy, and supply chain investments with the clinical and operational realities that govern uptake.

A multidimensional regional analysis revealing how Americas, Europe Middle East & Africa, and Asia-Pacific each shape regulatory strategy, manufacturing footprints, and patient access dynamics

Regional dynamics play a pivotal role in shaping production strategies, regulatory engagement, and patient access pathways across the industry. In the Americas, established manufacturing clusters and dense healthcare networks support widespread adoption of both plasma-derived and recombinant therapies, while policy and reimbursement environments continue to evolve around cost-effectiveness and equitable access. This region's research infrastructure and clinical trial capacity also make it a focal point for novel therapeutic evaluations and post-authorization safety monitoring.

In Europe, Middle East & Africa, regulatory harmonization efforts and diverse health system maturities produce a range of market entry considerations, from alignment with centralized approval frameworks to locally tailored access programs. Capacity constraints in certain markets within this region emphasize the importance of regional supply hubs, donor recruitment initiatives, and targeted patient support mechanisms. Meanwhile, Asia-Pacific presents a mix of rapidly growing demand, expanding local manufacturing capabilities, and variable regulatory pathways that collectively encourage strategic partnerships and licensing models to accelerate market entry. Across all regions, cross-border logistics, cold chain integrity, and local clinical practice patterns require manufacturers and distributors to adopt differentiated approaches to commercialization and operations to meet heterogeneous needs effectively.

An executive perspective on how incumbent producers, recombinant innovators, and contract manufacturers are reshaping competitive advantage through partnerships, modernization, and service differentiation

Competitive dynamics are shaped by a mix of legacy plasma fractionators, innovators in recombinant protein engineering, and specialized contract manufacturers that provide scale and technical expertise. Key players emphasize portfolio diversification, integrating plasma-derived offerings with recombinant therapeutics to balance supply risk and meet diverse clinical needs. Strategic priorities include investments in manufacturing modernization, expansion of pathogen-reduction technologies, and programs that strengthen donor recruitment and retention for plasma sourcing.

Collaborative models are increasingly common, with licensing deals, co-development partnerships, and contracted manufacturing agreements enabling faster time-to-market for novel formulations while mitigating capital intensity. Companies are also focusing on differentiated service models to support clinicians and patients, including enhanced patient education, adherence tools, and integrated home-care support for therapies suitable for at-home administration. Mergers and acquisitions activity continues to recalibrate competitive positioning as firms seek scale, geographic reach, and complementary technical capabilities to compete effectively in a landscape where product quality, supply resilience, and clinical support services are decisive factors.

Actionable recommendations focused on strengthening supply resilience, accelerating digital traceability, and aligning commercialization approaches with care settings and payer expectations

Leaders in the sector should prioritize integrated strategies that strengthen supply resilience while supporting clinical adoption and payer alignment. Investing in regional manufacturing and in redundant sourcing reduces vulnerability to trade disruptions and tariff-driven cost pressures, and concurrently supports faster response to local demand fluctuations. In parallel, organizations should accelerate adoption of digital quality systems and supply-chain traceability tools that enhance product safety oversight and regulatory compliance, thereby increasing confidence among clinicians and payers.

Commercially, firms will benefit from developing tailored access programs that address the needs of Hemophilia Treatment Centers, home-based care models, and hospital settings, ensuring distribution strategies align with each channel's operational needs. Strategic collaborations with clinical centers and patient advocacy groups can amplify real-world evidence collection and support reimbursement discussions. Finally, corporate decision-makers should embed scenario planning for policy and trade changes into capital investment assessments and partnership negotiations, ensuring that product portfolios and manufacturing footprints remain adaptable to shifting regulatory and economic conditions.

A transparent, mixed-methods research approach combining expert interviews, regulatory review, and scenario-based analysis to validate strategic insights and ensure methodological rigor

The research underpinning this analysis draws on a mixed-methods approach that synthesizes primary stakeholder engagement with rigorous secondary-source validation to create a robust and defensible evidence base. Qualitative inputs include structured interviews and consultation sessions with clinical experts, manufacturing leaders, regulatory affairs specialists, and distribution partners, designed to capture operational realities, adoption drivers, and perceived barriers across therapeutic categories. These perspectives are triangulated with technical literature, regulatory guidance documents, and publicly available clinical trial registries to ensure alignment with current scientific and policy contexts.

Analytical methods employ comparative scenario analysis to explore how changes in trade policy, manufacturing capacity, and distribution models affect strategic choices across stakeholders. A thematic synthesis approach is used to integrate insights from different segments and regions, highlighting cross-cutting trends and localized considerations without relying on proprietary or numerical market estimates. Quality assurance protocols include cross-validation of key findings by independent subject-matter reviewers and documented audit trails for source materials and interview protocols, ensuring transparency and reproducibility of the conclusions presented.

A conclusive synthesis emphasizing coordinated strategic responses that align scientific innovation, operational resilience, and tailored commercialization to improve patient access

In conclusion, the blood plasma derivatives and recombinant therapeutics landscape is marked by simultaneous opportunities and challenges that demand coordinated strategic responses. Scientific progress in recombinant engineering and improvements in plasma fractionation technology are expanding therapeutic options, while regulatory and payer expectations are heightening the emphasis on safety, traceability, and demonstrable real-world outcomes. Supply chain fragilities and geopolitical trade variables further complicate operational planning, underscoring the importance of diversified sourcing and regional capacity investments.

Stakeholders that proactively align R&D priorities, manufacturing strategies, and commercialization models with the differentiated needs of treatment centers, home-care programs, and hospital systems will be best positioned to deliver value to patients and health systems. By integrating robust risk-management practices, embracing digital quality tools, and cultivating collaborative partnerships, organizations can enhance resilience and accelerate the adoption of therapies that address pressing clinical needs. The sector's trajectory will be shaped by those who combine scientific excellence with operational foresight and pragmatic engagement with clinical and policy stakeholders, thereby translating innovation into sustainable patient impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emerging recombinant albumin therapies reducing reliance on donated plasma proteins
  • 5.2. Expansion of immunoglobulin demand due to increased autoimmune disorder prevalence
  • 5.3. Adoption of advanced viral inactivation technologies for enhanced plasma product safety
  • 5.4. Regulatory harmonization efforts accelerating global approval of plasma-derived therapeutics
  • 5.5. Strategic partnerships between plasma fractionation companies and biotech innovators
  • 5.6. Rising use of hyperimmune globulins for infectious disease management and pandemic response
  • 5.7. Shift towards subcutaneous immunoglobulin administration improving patient adherence and comfort
  • 5.8. Implementation of digital plasma donor management platforms optimizing collection and tracing
  • 5.9. Investment in single-use bioreactor systems for decentralized plasma fractionation capacity
  • 5.10. Development of monoclonal antibody adjuncts integrating with plasma derivatives for targeted therapy

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Plasma Derivatives Market, by Source

  • 8.1. Plasma Derived
  • 8.2. Recombinant
    • 8.2.1. Factor IX
    • 8.2.2. Factor VIII

9. Blood Plasma Derivatives Market, by End User

  • 9.1. Hemophilia Treatment Centers
  • 9.2. Home Care
  • 9.3. Hospitals

10. Blood Plasma Derivatives Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacy
  • 10.4. Specialist Clinics

11. Blood Plasma Derivatives Market, by Product Type

  • 11.1. Albumin
  • 11.2. Coagulation Factor
    • 11.2.1. Factor IX
    • 11.2.2. Factor VIII
    • 11.2.3. Fibrin Sealant
  • 11.3. Immunoglobulin
    • 11.3.1. Hyperimmune
    • 11.3.2. Intravenous
    • 11.3.3. Subcutaneous

12. Blood Plasma Derivatives Market, by Application

  • 12.1. Hemophilia Treatment
  • 12.2. Neurological Disorders
  • 12.3. Primary Immunodeficiency

13. Blood Plasma Derivatives Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Blood Plasma Derivatives Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Blood Plasma Derivatives Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. CSL Limited
    • 16.3.2. Grifols, S.A.
    • 16.3.3. Takeda Pharmaceutical Company Limited
    • 16.3.4. Octapharma AG
    • 16.3.5. Kedrion S.p.A.
    • 16.3.6. Biotest AG
    • 16.3.7. LFB S.A.
    • 16.3.8. Bio Products Laboratory Limited
    • 16.3.9. Shanghai RAAS Blood Products Co., Ltd.
    • 16.3.10. China Biologic Products Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BLOOD PLASMA DERIVATIVES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BLOOD PLASMA DERIVATIVES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BLOOD PLASMA DERIVATIVES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PLASMA DERIVED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PLASMA DERIVED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PLASMA DERIVED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PLASMA DERIVED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PLASMA DERIVED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PLASMA DERIVED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMOPHILIA TREATMENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMOPHILIA TREATMENT CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMOPHILIA TREATMENT CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMOPHILIA TREATMENT CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMOPHILIA TREATMENT CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMOPHILIA TREATMENT CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SPECIALIST CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SPECIALIST CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SPECIALIST CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SPECIALIST CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FIBRIN SEALANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FIBRIN SEALANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FIBRIN SEALANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FIBRIN SEALANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FIBRIN SEALANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FIBRIN SEALANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HYPERIMMUNE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HYPERIMMUNE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HYPERIMMUNE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HYPERIMMUNE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HYPERIMMUNE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HYPERIMMUNE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMOPHILIA TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMOPHILIA TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMOPHILIA TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMOPHILIA TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMOPHILIA TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMOPHILIA TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. ASEAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. ASEAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. ASEAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2024 (USD MILLION)
  • TABLE 310. ASEAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2025-2032 (USD MILLION)
  • TABLE 311. ASEAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 312. ASEAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 313. ASEAN BLOOD PLASMA DERIVATIV